Illumina Announces Appointments of Elizabeth Brady as Vice President, Global Supply Chain, & Emily Winn-Deen as Vice Presiden...
April 30 2010 - 6:00AM
Business Wire
Illumina, Inc. (NASDAQ:ILMN) today announced the appointments of
Elizabeth Brady as vice president, Global Supply Chain, and Emily
S. Winn-Deen, Ph.D., as vice president, Diagnostics
Development.
Ms. Brady will be responsible for Illumina’s global sourcing,
planning, logistics and distribution operations, reporting to
William Bonnar, senior vice president, Operations. “Elizabeth has
an outstanding background as a senior leader with extensive global
experience in supply chain management spanning the electronics and
healthcare industries,” said Mr. Bonnar. “At Illumina, she will
play a critical role in building a world-class supply chain
operation that will be a key element in realizing our growth
objectives.”
Prior to joining Illumina, Ms. Brady served as vice president,
Global Supply Chain, Cardiac Rhythm Management Division of Boston
Scientific Corporation, where she built a supply chain organization
that helped successfully launch new products, reduce obsolete
inventory, implement life cycle management and reduce planning
cycle time. Previously, she served as vice president, Supply Chain,
at Tellabs Operations, Inc., a maker of telecom infrastructure
equipment. She also held supply chain leadership positions in the
U.S. and Ireland with 3Com Corporation. Ms. Brady holds a B.S. in
Business Analysis and Business Economics from Indiana University,
Bloomington.
Dr. Winn-Deen will be responsible for the development of
diagnostics products at Illumina, reporting to Gregory Heath,
Ph.D., senior vice president and general manager, Diagnostics.
“Emily brings an impressive track record of more than 20 years of
successful leadership in the life sciences and diagnostics fields,
much of it focused on novel biomarkers and product development for
emerging markets,” said Dr. Heath. “As head of development, she
will play a crucial role in building Illumina’s diagnostics
capability and paving the way for our future leadership in this
critical area.”
Prior to joining Illumina, Dr. Winn-Deen served as president of
Rx Dx Advisors, a consulting practice focused on evaluating market
trends and new technology, corporate partnering, business and
product development, and regulatory compliance. Previously, at
Cepheid, she held vice president positions in Genetics and Oncology
R&D, and in Strategic Development and Business Planning. She
has served in senior R&D positions at a range of diagnostics
and pharmaceutical companies, including Roche Molecular Systems,
Applera Corporation, Oncor and Bayer Diagnostics. Dr. Winn-Deen
holds a B.A. in chemistry from Lehigh University and a Ph.D. in
chemistry from Boston University.
About Ms. Brady’s and Dr. Winn-Deen’s Compensation
Illumina granted an option to purchase 120,000 shares of
Illumina's common stock to Ms. Brady and an option to purchase
112,000 shares of Illumina’s common stock to Dr. Winn-Deen, as part
of their inducement to join the company. The options were granted
by Illumina’s Compensation Committee pursuant to NASDAQ Marketplace
Rule 5635(c)(4) and under Illumina's New Hire Stock and Incentive
Plan, which was approved by Illumina's Board of Directors on
January 29, 2008. These options have the following terms: an
exercise price equal to the closing fair market value of Illumina's
common stock on the grant date, a ten-year term, and vesting over
four years with 25 percent of the option vesting one year from the
grant date and 1/48th of the option vesting monthly thereafter. The
grant date for the option to Ms. Brady is May 3, 2010. The
grant date for the option to Dr. Winn-Deen is April 26, 2010.
For more information about careers at Illumina, please visit
www.illumina.com/careers.
About Illumina
Illumina (http://www.illumina.com) is a leading developer,
manufacturer, and marketer of life-science tools and integrated
systems for the large-scale analysis of genetic variation and
biological function. Using our proprietary technologies, we provide
a comprehensive line of products and services that currently serve
the sequencing, genotyping, and gene expression markets, and we
expect to enter the market for molecular diagnostics. Our customers
include leading genomic research centers, pharmaceutical companies,
academic institutions, clinical research organizations, and
biotechnology companies. Our tools provide researchers around the
world with the performance, throughput, cost effectiveness, and
flexibility necessary to perform the billions of genetic tests
needed to extract valuable medical information from advances in
genomics and proteomics. We believe this information will enable
researchers to correlate genetic variation and biological function,
which will enhance drug discovery and clinical research, allow
diseases to be detected earlier, and permit better choices of drugs
for individual patients.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Jul 2023 to Jul 2024